"10.1371_journal.pone.0030107","plos one","2012-01-17T00:00:00Z","Vivian Chen; Richard E Staub; Scott Baggett; Ramesh Chimmani; Mary Tagliaferri; Isaac Cohen; Emma Shtivelman","BioNovo, Inc., Emeryville, California, United States of America","Conceived and designed the experiments: ES RS IC. Performed the experiments: ES VC RS SB RC. Analyzed the data: ES RS MT IC. Wrote the paper: ES RS.","The authors declare a financial competing interest. The authors acknowledge that they are paid employees and stock holders of BioNovo, Inc, and that this study, in its entirety, was supported by funds from BioNovo. Bezielle (BZL101) is Bionovos proprietary botanical drug candidate (FDA-IND: 59,521) for the treatment of metastatic breast cancer. Bionovos United States Patent No. 7,700,136 covers a method of treating breast cancer using an extract of Scutellaria Barbata. This patent also covers the use of Bionovos proprietary BezielleR formulation as a monotherapy for the treatment of breast cancer. This does not alter the authors adherence to all the PLoS ONE policies on sharing data and materials.","2012","01","Vivian Chen","VC",7,TRUE,3,5,4,2,TRUE,FALSE,FALSE,0,NA,FALSE
